References
Shapiro J, van Hagen P, Lingsma HF, et al. Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer. Ann Surg. 2014;260:807–13. https://doi.org/10.1097/sla.0000000000000966.
Nilsson K, Klevebro F, Rouvelas I, et al. Surgical morbidity and mortality from the multicenter randomized controlled NeoRes II Trial: standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg. 2020;272:684–9. https://doi.org/10.1097/sla.0000000000004340.
Xiao X, Cheng C, Cheng L, et al. Longer time interval from neoadjuvant chemoradiation to surgery is associated with poor survival for patients without clinical complete response in oesophageal cancer. Ann Surg Oncol. 2023;30:886–96. https://doi.org/10.1245/s10434-022-12758-9.
Nilsson K, Klevebro F, Sunde B, et al. Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled NeoRes II trial. Ann Oncol. 2023;34:1015–24. https://doi.org/10.1016/j.annonc.2023.08.010.
Li J, Zhou X, Liu Y, et al. Optimal time-to-surgery recommendations based on primary tumor volume regression for patients with resectable esophageal cancer after neoadjuvant chemoradiotherapy. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-14941-6.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article refers to: Li J, Zhou X, Liu Y, et al. Optimal time-to-surgery recommendations based on primary tumor volume regression for patients with resectable esophageal cancer after neoadjuvant chemoradiotherapy. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-14941-6.
Rights and permissions
About this article
Cite this article
Li, J., Wang, Q. ASO Author Reflections: Fathoming the Dilemma of the Optimal Time to Surgery for Patients with Resectable Esophageal Cancer After Neoadjuvant Chemoradiotherapy. Ann Surg Oncol 31, 3852–3853 (2024). https://doi.org/10.1245/s10434-024-14989-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-024-14989-4